Ablevia biotech GmbH
ABLEVIA biotech is owner of the SADC-platform technology for the selective depletion of disease-causing and neutralizing antibodies. SADCs are first-in-class, infusible therapeutics, a flexible technology readily adaptable to several disease- and ADA-indications including unmet clinical needs. This technology solves critical issues in a wide array of therapeutic contexts, such as drug inhibition, autoimmune diseases, organ transplantation, gene therapy.
Presenter: Oskar Smrzka, Founder and Inventor, Ablevia biotech GmbH